Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viewpoint: expanding prostate cancer screening.

William J Catalona1, Stacy Loeb, Misop Han

  • 1Northwestern Feinberg School of Medicine, Department of Urology, Chicago, Illinois 60611, USA. wcatalona@nmff.org

Annals of Internal Medicine
|March 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in Industry-Sponsored Research Payments to Otolaryngologist Principal Investigators.

The Laryngoscope·2026
Same author

Trends in Industry-sponsored Research Payments to Anesthesiologist Principal Investigators.

Anesthesiology·2026
Same author

Trends in Industry-Sponsored Research Payments and General Payments to Neurologists: Open Payments Program 2015-2023.

Neurology. Clinical practice·2026
Same author

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation.

The Prostate·2026
Same author

Trends in Research Payments From Industry to Dermatologists.

Cureus·2025
Same author

Trends in Industry-Sponsored Research Payments to Radiologist Principal Investigators.

Journal of the American College of Radiology : JACR·2025
Same journal

The Role of Telemedicine on Interhospital Transfer Outcomes : A Systematic Review.

Annals of internal medicine·2026
Same journal

Prolonged Short Sleep and Its Effect on Body Weight and Composition : A Pooled Analysis of Randomized Trials.

Annals of internal medicine·2026
Same journal

In AF, LAAC was noninferior to NOAC therapy for a composite efficacy outcome and reduced non-procedure-related bleeding at 3 y.

Annals of internal medicine·2026
Same journal

How AI is affecting medical journals.

Annals of internal medicine·2026
Same journal

In adults with COPD, the BLISS score predicted risk for acute respiratory hospital admission at 2 y.

Annals of internal medicine·2026
Same journal

In AF at risk for stroke and bleeding, LAAC was not noninferior to medical therapy for a composite of thromboembolic and safety events.

Annals of internal medicine·2026
See all related articles

Prostate cancer screening using prostate-specific antigen (PSA) is effective. Recommendations include starting screening at age 40 for average-risk men, continuing for select healthy men over 70, and lowering the biopsy threshold to 2.5 ng/mL.

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Background:

  • Prostate cancer screening guidelines differ among professional organizations.
  • Controversy exists regarding the efficacy and optimal implementation of prostate cancer screening.
  • Recent evidence since 2000 supports the benefits of prostate-specific antigen (PSA) screening.

Purpose of the Study:

  • To address key issues in prostate cancer screening: biopsy criteria, initiation age, and cessation age.
  • To evaluate the evidence for PSA screening efficacy.
  • To provide updated recommendations for prostate cancer screening protocols.

Main Methods:

  • Review of scientific evidence published since 2000 concerning PSA screening efficacy.
  • Analysis of data to determine optimal screening ages and PSA thresholds.

Related Experiment Videos

  • Formulation of recommendations based on current evidence.

    • Main Results:

    • Evidence supporting the efficacy of PSA screening is considered convincing.
    • Recommended starting age for average-risk men is 40 years.
    • Selected healthy men over 70 years should continue screening.
    • Recommended PSA threshold for biopsy consideration is lowered to 2.5 ng/mL.

    Conclusions:

    • PSA screening is effective for prostate cancer risk assessment.
    • Screening protocols should be individualized based on risk and health status.
    • Updated guidelines can improve prostate cancer detection and management.